Answers are grounded in this paper and cite their sources.
Chronic diabetic ulcers are a main complication of diabetes mellitus and frequently require effective treatment to advance wound healing and prevent complications. This study evaluated topical Recombinant Human Epidermal Growth Factor (rhEGF) compared with conventional saline dressing for managing chronic diabetic ulcers. We conducted a randomized controlled trial at a tertiary care teaching hospital from September 2022 to May 2024. A total of 100 patients with diabetic foot ulcers were randomly assigned to receive each topical rhEGF ointment (Group A, n = 50) or conventional saline dressing (Group B, n = 50). Wound size was assessed at baseline, Day 7, and Day 14 using the graph paper method. The primary result was a reduction in wound size. Baseline demographic and clinical variables were comparable among the groups. By Day 14, Group A demonstrated a significantly smaller mean wound size than Group B (5.78 ± 2.64 cm 2 vs 8.33 ± 3.71 cm 2 ; P = .0001). Topical rhEGF was associated with greater short-term reduction in wound surface area compared with conventional saline dressing over 14 days. These findings indicate a potential short-term benefit in wound-area reduction during inpatient treatment; however, complete wound healing, time to healing, recurrence, amputation, graft take, adverse events, and post-discharge outcomes were not assessed. These findings therefore should not be interpreted as evidence of improved overall healing or long-term clinical effectiveness.
No takes yet. Share an insight, caveat, or question.
Bosco et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: